Hsbc Holdings PLC Denali Therapeutics Inc. Transaction History

Hsbc Holdings PLC

$176 Billion
Q3 2025

A detailed history of Hsbc Holdings PLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 14,004 shares of DNLI stock, worth $244,229. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,004

Previous 10,048 39.37%

Holding current value

$244,229

Previous $140,000 45.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$12.75 - $15.65 $50,439 - $61,911	3,956 Added 39.37%	14,004 $203,000
Q2 2025 Aug 13, 2025	SELL	$11.47 - $16.65 $550,043 - $798,450	-47,955 Reduced 82.68%	10,048 $140,000
Q1 2025 May 14, 2025	BUY	$13.6 - $23.59 $334,736 - $580,620	24,613 Added 73.71%	58,003 $788,000
Q4 2024 Feb 14, 2025	BUY	$20.24 - $31.58 $131,701 - $205,491	6,507 Added 24.2%	33,390 $680,000
Q3 2024 Nov 14, 2024	SELL	$20.96 - $31.05 $57,828 - $85,666	-2,759 Reduced 9.31%	26,883 $783,000

Q2 2024 Aug 12, 2024	BUY	$14.96 - $23.22 $201,271 - $312,401	13,454 Added 83.11%	29,642 $688,000
Q1 2024 May 15, 2024	SELL	$15.83 - $23.35 $11,144 - $16,438	-704 Reduced 4.17%	16,188 $332,000
Q4 2023 Feb 12, 2024	SELL	$16.2 - $23.18 $8,667 - $12,401	-535 Reduced 3.07%	16,892 $362,000
Q3 2023 Nov 13, 2023	BUY	$20.63 - $30.17 $359,519 - $525,772	17,427 New	17,427 $359,000
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $92,109 - $137,344	4,204 Added 44.97%	13,553 $312,000
Q4 2022 Feb 14, 2023	BUY	$26.28 - $33.92 $44,019 - $56,816	1,675 Added 21.83%	9,349 $259,000
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $199,293 - $295,679	7,674 New	7,674 $239,000

Others Institutions Holding DNLI

# of Institutions

259

Shares Held

133M

Call Options Held

219K

Put Options Held

107K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.34B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Denali Therapeutics Inc. Transaction History